Goldenwell Biotech Changes Certifying Accountant
Ticker: GWLL · Form: 8-K · Filed: Aug 19, 2025 · CIK: 1800373
| Field | Detail |
|---|---|
| Company | Goldenwell Biotech, INC. (GWLL) |
| Form Type | 8-K |
| Filed Date | Aug 19, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, 8-k
Related Tickers: GDWL
TL;DR
GDWL changed its auditor on 7/24. Keep an eye on financials.
AI Summary
Goldenwell Biotech, Inc. filed an 8-K on August 19, 2025, reporting a change in its certifying accountant as of July 24, 2025. The company's principal executive offices are located at 7316 Capilano Dr., Solon, Ohio. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
A change in a company's auditor can signal potential concerns about financial reporting or internal controls, warranting closer scrutiny by investors.
Risk Assessment
Risk Level: medium — Changes in certifying accountants can sometimes precede or indicate underlying financial issues or disagreements.
Key Players & Entities
- GOLDENWELL BIOTECH, INC. (company) — Registrant
- July 24, 2025 (date) — Date of earliest event reported
- August 19, 2025 (date) — Filing Date
- 7316 Capilano Dr. Solon , Ohio 44139 (address) — Principal executive offices
FAQ
What is the primary reason for the change in Goldenwell Biotech's certifying accountant?
The filing states it is a change in registrant's certifying accountant, but does not provide specific reasons for the change.
When was the change in certifying accountant effective?
The change was effective as of July 24, 2025.
What is Goldenwell Biotech, Inc.'s state of incorporation?
Goldenwell Biotech, Inc. is incorporated in Nevada.
What is the company's SIC code and industry?
The company's SIC code is 2000, which corresponds to FOOD & KINDRED PRODUCTS.
What is the filing date of this 8-K report?
This 8-K report was filed on August 19, 2025.
Filing Stats: 832 words · 3 min read · ~3 pages · Grade level 13.5 · Accepted 2025-08-19 06:30:03
Filing Documents
- gdwl_8k.htm (8-K) — 24KB
- gdwl_ex161.htm (EX-16.1) — 4KB
- gdwl_ex161img3.jpg (GRAPHIC) — 4KB
- 0001477932-25-006051.txt ( ) — 140KB
- gdwl-20250724.xsd (EX-101.SCH) — 5KB
- gdwl-20250724_lab.xml (EX-101.LAB) — 13KB
- gdwl-20250724_cal.xml (EX-101.CAL) — 1KB
- gdwl-20250724_pre.xml (EX-101.PRE) — 8KB
- gdwl-20250724_def.xml (EX-101.DEF) — 2KB
- gdwl_8k_htm.xml (XML) — 3KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant (a) On July 24, 2025, KCCW Accountancy Corp. ("KCCW") notified Goldenwell Biotech, Inc. (the "Company") it had resigned as the independent registered public accounting firm of the Company. The report of KCCW regarding the Company's financial statements as of December 31, 2024 and 2023 and the statement of operations, stockholders' equity (deficit) and cash flows for the years then ended, contained no adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principle. The report of KCCW, however, stated that there is substantial doubt about the Company's ability to continue as a going concern. For the years ended December 31, 2024 and 2023, and during the subsequent interim period through the date of dismissal, the Company had no disagreement with KCCW on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved to the satisfaction of KCCW, would have caused them to make reference thereto in their report on the Company's financial statements for such year ended December 31, 2024 and 2023. There were no reportable events, as listed in Item 304(a)(1)(v) of Regulation S-K. The Company provided KCCW a copy of the above disclosures and requested KCCW to furnish a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the above statements. KCCW's response is attached as Exhibit 16.1 to this Current Report on Form 8-K. (b) On August 14, 2025, the board of directors of the Company resolved to engage the independent registered public accounting firm Michael Gillespie & Associates, PLLC ("Michael Gillespie & Associates"), as the Company's new independent registered public accountants, which appointment Michael Gillespie & Associates has accepted. Michael Gillespie & Associates most recently served as the Company's in
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits: Exhibit Description 16.1 Letter from KCCW Accountancy Corp., dated August 18, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GOLDENWELL BIOTECH, INC. Date: August 18, 2025 By: /s/ Shuang Liu Name: Shuang Liu Title: Chief Executive Officer 3